Bleakley Financial Group LLC Has $708,000 Stake in West Pharmaceutical Services, Inc. (NYSE:WST)

Bleakley Financial Group LLC raised its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 3.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,358 shares of the medical instruments supplier’s stock after purchasing an additional 76 shares during the quarter. Bleakley Financial Group LLC’s holdings in West Pharmaceutical Services were worth $708,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. LGT Group Foundation bought a new stake in shares of West Pharmaceutical Services in the 2nd quarter worth $68,854,000. Liontrust Investment Partners LLP purchased a new stake in West Pharmaceutical Services in the 2nd quarter valued at about $64,196,000. Findlay Park Partners LLP lifted its position in shares of West Pharmaceutical Services by 30.6% during the 1st quarter. Findlay Park Partners LLP now owns 597,106 shares of the medical instruments supplier’s stock worth $236,281,000 after buying an additional 139,800 shares in the last quarter. Iron Triangle Partners LP purchased a new position in shares of West Pharmaceutical Services in the 1st quarter worth approximately $47,381,000. Finally, ProShare Advisors LLC grew its holdings in shares of West Pharmaceutical Services by 13.9% in the first quarter. ProShare Advisors LLC now owns 500,662 shares of the medical instruments supplier’s stock valued at $198,117,000 after acquiring an additional 61,247 shares in the last quarter. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Performance

Shares of West Pharmaceutical Services stock opened at $287.25 on Tuesday. The business’s fifty day simple moving average is $299.96 and its 200 day simple moving average is $324.52. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03. West Pharmaceutical Services, Inc. has a 12 month low of $265.00 and a 12 month high of $413.70. The firm has a market capitalization of $20.84 billion, a P/E ratio of 40.86, a price-to-earnings-growth ratio of 10.46 and a beta of 1.01.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The business had revenue of $702.10 million for the quarter, compared to the consensus estimate of $729.36 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The company’s revenue for the quarter was down 6.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.11 earnings per share. As a group, analysts anticipate that West Pharmaceutical Services, Inc. will post 6.42 EPS for the current year.

Insiders Place Their Bets

In other news, VP Charles Witherspoon sold 1,029 shares of the stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $300.00, for a total transaction of $308,700.00. Following the completion of the transaction, the vice president now directly owns 1,478 shares of the company’s stock, valued at $443,400. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.53% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.